secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2026-09-30T20:15:40+00:00
Accession:  0001628280-26-063981
Event type: litigation
Sentiment:  positive
Materiality: 0.68
Item codes: 1.01
LLM model:  deepseek-v4.1-flash:cloud@v2

BioMarin settles patent suit with Ascendis; wins 20% US royalty on TransCon CNP through May 2030
--------------------------------------------------------------------------------

- BioMarin grants Ascendis a non-exclusive, worldwide, transferable, royalty-bearing license to BioMarin Patent Rights covering navepegritide (TransCon CNP)/Yuviwel, effective August 28, 2026.
- Royalty is 20% of annual US net sales and 18% of net sales in the EU, Brazil and South Korea, running from first commercial sale in each territory until May 2030.
- All pending litigation between the parties over the BioMarin Patent Rights will be dismissed with prejudice; BioMarin releases pre-effective-date infringement claims and covenants not to sue Ascendis.
- Ascendis covenants not to challenge BioMarin's Patent Rights, plus a mutual regulatory non-interference clause; licensed products cover achondroplasia and hypochondroplasia, alone or in combination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/0001628280-26-063981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-063981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer